Anesthesia · Local AnestheticRegulatory Approvalregulatorymid-term

Anthea Pharma's Bupivacaine Hydrochloride ANDA220493 Receives AP Status

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/5/2026, 12:34:18 PM

Assessment confidence: 74% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Anthea Pharma's Bupivacaine Hydrochloride ANDA220493 signifies a new entrant in the local anesthetic market, which could disrupt existing competitive dynamics. Pharma strategy teams should consider the implications for pricing and market positioning as competition intensifies. Regulatory context from FDA (FDA AP — BUPIVACAINE HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 21 ranked evidence items (13 high-relevance).

Strategic Assessment

Anthea Pharma should prepare for market entry strategies and consider pricing to effectively compete with established players. The strongest clinical anchor is Intraperitoneal Ketamine Versus Fentanyl as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy (ClinicalTrials.gov), moderate corpus alignment. In Anesthesia · Local Anesthetic, 8 regulatory and 5 competitive items passed relevance filtering for Anthea Pharma.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from [Ad hoc announcement pursuant to Art.. This approval may enable Anthea Pharma to enter the local anesthetic market, increasing competition against existing products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — BUPIVACAINE HYDROCHLORIDE (ORIG) (FDA). Entity match (anthea pharma); Regulatory pathway relevance (nda). The approval status indicates compliance with FDA standards, but ongoing monitoring of market launch and competitor responses will be crucial.

Key Risks

Elevated medium regulatory exposure for Anthea Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Anthea Pharma's entry may lead to price competition, affecting revenue streams for established players in the local anesthetic market.
Upside for Anthea Pharma may improve if Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Lead sponsor: Sichuan Credit Pharmaceutical Co., Ltd.. An open-label, randomized, single dose study to assess dose proportionality and pharmacokinetic linearity in healthy participants under fasting condition.
Anthea Pharma should prepare for market entry strategies and consider pricing to effectively compete with established players.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for market launch and any potential challenges from competitors.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — BUPIVACAINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (anthea pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIPHENHYDRAMINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Intraperitoneal Ketamine Versus Fentanyl as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
To Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants Under Fasting Conditions
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA to Terminate Emergency Use Authorizations for COVID-19 Drugs
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of different liposomal bupivacaine concentrations in ultrasound-guided superior trunk block on postoperative analgesia and mobility: a randomized double-blind controlled trial protocol for shou
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Thoracic paravertebral block with different doses of liposomal bupivacaine versus ropivacaine for postoperative analgesia in single-port thoracoscopic lung surgery: a randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Anthea Pharma
Bupivacaine Hydrochloride

Commercial impact

medium

Anthea Pharma's entry may lead to price competition, affecting revenue streams for established players in the local anesthetic market.

Regulatory impact

medium

The approval status indicates compliance with FDA standards, but ongoing monitoring of market launch and competitor responses will be crucial.

What to watch

Monitor the timeline for market launch and any potential challenges from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.